Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| SMARCA2 |
|
|
| SMARCA4 |
|
|
| PBRM1 |
|
|
Selectivity
Potency Cellular
In Vitro
Mode of Action: Degrader (PROTAC)
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/s41589-019-0294-6
Mode of Action: Degrader (PROTAC)
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/s41589-019-0294-6
Mode of Action: Degrader (PROTAC)
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/s41589-019-0294-6
Negative Control Compounds
Notes: In the negative control compound, cis-ACBI1, the hydroxy proline of the VHL binding part is in the inactive cis-conformation, which prevents binding to VHL and thereby protein degradation. This prevents binding to VHL, formation of a triple complex and thereby protein degradation. This compound is useful to differentiate phenotypic effects not caused by protein degradation in comparison with its active trans isomer ACBI1. Furthermore, the difference between binding to the bromodomain of SMARCA2 and SMARCA4 and its degradation can be studied in vitro.
Chemical Information
| Molecular Formula | C49H58FN9O7S |
| SMILEs | Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)c(OCCOc2ccc(CN3CCN(c4cc(-c5ccccc5O)nnc4N)CC3)cc2)c1 |
| InChI | InChI=1S/C49H58FN9O7S/c1-30-42(67-29-53-30)32-11-12-33(26-52-45(62)39-24-34(60)28-59(39)46(63)43(48(2,3)4)54-47(64)49(50)15-16-49)41(23-32)66-22-21-65-35-13-9-31(10-14-35)27-57-17-19-58(20-18-57)38-25-37(55-56-44(38)51)36-7-5-6-8-40(36)61/h5-14,23,25,29,34,39,43,60-61H,15-22,24,26-28H2,1-4H3,(H2,51,56)(H,52,62)(H,54,64)/t34-,39+,43-/m1/s1 |
| Molecular weight | 935.42 Da |
| AlogP | 5.254320000000003 |
| HBond acceptors | 16 |
| HBond donors | 6 |
| Atoms | 125 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the Portal.